ArticleScientific reports2025
Safety assessment and in vitro cytotoxicity profiling of fruiting bodies from Lentinula edodes (shiitake) strains in HeLa and MCF-7 cell lines.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Edible and Medicinal Mushrooms as Sources of Bioactive Molecules in Pregnancy: Potential Impact on Preeclampsia and Gestational Diabetes Outcomes.Molecules (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Medicinal mushrooms offer diverse therapeutic benefits, but proper administration is crucial to avoid long-term health issues linked to fungal toxicity. This study evaluated the safety and in vitro cytotoxic potential of Lentinula edodes (shiitake) mushrooms for broader use in food and health supplements. Two strains, DMRO-34 and DMRO-356, were tested for cytotoxic and nutraceutical properties. In vitro analysis using MTT and LDH assays on human cervical (HeLa) and breast cancer (MCF-7) cell lines showed that DMRO-356 exhibited greater anti-proliferative effects compared to DMRO-34. β-glucan content was quantified in both strains using a Megazyme assay as part of the compositional profile. In vivo studies with a limit dose of 5000 mg/kg body weight assessed acute and sub-acute toxicity over 14 and 28 days. Both strains showed no observable adverse effects (NOAEL) in rats, confirming their safety at the tested dose. The results indicate that L. edodes may possess bioactive properties and are well-tolerated in animal models. While the in vitro cytotoxic effects are promising, the in vivo results presented here establish their safety profile; however, further in vivo efficacy investigations are required to validate their therapeutic potential. Overall, these findings suggest that DMRO-34 and DMRO-356 are safe for use and may act as natural therapeutic agents, with DMRO-356 showing greater efficacy. This study supports the safe incorporation of L. edodes mushrooms into dietary supplements and functional foods, and highlights their potential role in adjunct strategies for cancer prevention and immune support.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.